Aspire Biopharma Announces $21 Million Private Placement

Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) announced a $21 million private placement with select institutional and accredited investors. The company issued 26,250 shares of Series A Convertible Preferred Stock at $800 per share, with an initial closing of 13,750 shares for $11 million in gross proceeds. The funds will be used to support operations, fund initiatives, and pay offering expenses, as well as help the company regain compliance with Nasdaq's stockholders' equity listing requirements.

Why it matters

The private placement strengthens Aspire Biopharma's balance sheet and capital position, providing additional resources to advance its clinical and development initiatives for its patent-pending drug delivery technologies. Regaining Nasdaq compliance is a key milestone for the company as it looks to support long-term shareholder value.

The details

Aspire Biopharma entered into a securities purchase agreement on February 6, 2026 with select investors for the purchase and sale of up to 26,250 shares of Series A Convertible Preferred Stock at $800 per share. The initial closing on February 6 issued 13,750 preferred shares for $11 million in gross proceeds, with the second closing expected at a later date. A portion of the proceeds will be used to support operations, fund strategic initiatives, and pay offering-related expenses, as well as help the company regain compliance with Nasdaq's stockholders' equity listing requirements.

  • The initial closing of the private placement occurred on February 6, 2026.
  • The second closing of the offering is expected to occur at a later date.

The players

Aspire Biopharma Holdings, Inc.

A biopharmaceutical company developing patent-pending drug delivery technology.

RBW Capital Partners LLC

The sole placement agent for the private placement, whose securities and brokerage services are offered through Dawson James Securities, Inc.

Got photos? Submit your photos here. ›

What’s next

The second closing of the offering is expected to occur at a later date and remains subject to the satisfaction of customary closing conditions and the other conditions set forth in the Securities Purchase Agreement.

The takeaway

The private placement strengthens Aspire Biopharma's financial position and provides the resources needed to advance its drug delivery technology development, while also helping the company regain compliance with Nasdaq's listing requirements, an important milestone for the company's long-term growth.